The global oncology based in-vivo CRO market reached a value of US$ 1.05 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 1.69 Billion by 2027, exhibiting a CAGR of 7.81% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Oncology refers to a branch of medicine that studies, diagnoses, and treats cancer using biopsy, endoscopy, X-ray, computed tomography (CT) scanning, magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, and ultrasound. It offers hormonal therapy, immunotherapy, radiotherapy, and oral therapies to patients for tolerating and easing the side effects of cancer. At present, there is a rise in the demand for oncology based in-vivo CRO across the globe due to the development of several investigational compounds by contract research organizations (CROs) for treating cancer.

Oncology Based In-Vivo CRO Market Trends:
The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities. This, along with the rising expertise in cancer treatment by contract research organizations (CROs), is propelling the growth of the market. In addition, there is an increase in the innovation of genetic engineering for manipulating deoxyribonucleic acid (DNA) and altering the characteristics of organisms. This, coupled with the growing focus on oncogene study to regulate proliferation, growth, and differentiation of cells, is positively influencing the market. Besides this, the wide availability of medicines, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Apart from this, the cost-efficiency offered by contract research organizations (CROs) compared to an in-house study is offering lucrative growth opportunities to industry investors. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry for ensuring the safety of cancer patients. This is projected to bolster the growth of the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology based in-vivo CRO market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on indication, model and application.

Breakup by Indication:

Blood Cancer
Solid Tumors
Others

Breakup by Model:

Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
Others

Breakup by Application:

Hospitals
Rehabilitation Centers

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec and Xentech.

Key questions answered in this report:
How has the global oncology based in-vivo CRO market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global oncology based in-vivo CRO market?
What are the key regional markets?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the model?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global oncology based in-vivo CRO market and who are the key players?
What is the degree of competition in the industry?